Skip to main navigation
Skip to search
Skip to main content
Sort by
INIS
patients
100%
lymphomas
54%
diseases
40%
stem cells
27%
therapy
24%
laboratories
23%
populations
20%
netherlands
19%
risks
18%
refractories
18%
phenotype
15%
tumors
14%
myeloid leukemia
14%
hemophilia
14%
comparative evaluations
13%
testing
13%
reviews
13%
management
13%
doses
12%
validation
12%
humans
12%
central nervous system
12%
breasts
12%
pregnancy
12%
hemorrhage
12%
women
11%
congenital diseases
10%
adults
10%
data
10%
leukemia
9%
induction
9%
antigens
9%
thrombosis
9%
levels
8%
hemostatics
8%
prophylaxis
8%
chemotherapy
8%
reduction
7%
cancer
7%
symptoms
7%
receptors
7%
control
7%
surgery
7%
matrices
7%
plasma
6%
nk cells
6%
transfusions
6%
detection
6%
utilities
6%
antibodies
6%
toxicity
6%
methotrexate
6%
mutations
6%
fibrinogen
6%
systems analysis
6%
grafts
6%
host
6%
immunosuppression
6%
natural killer cells
6%
body composition
6%
nutrition
6%
inflammation
6%
engineering
6%
bones
6%
surveys
6%
implants
6%
cars
6%
globulins
6%
thymocytes
6%
aplastic anemia
6%
artificial intelligence
6%
algorithms
6%
carriers
6%
genes
6%
range
5%
hazards
5%
Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
22%
Unknown Cause
18%
Bleeding Disorders
18%
Overall Survival
17%
Confidence Interval
13%
Netherlands
13%
Von Willebrand Disease
12%
High-dose Methotrexate (HD-MTX)
12%
Population-based Cohort Study
12%
Relapsed or Refractory
12%
Chemotherapy
11%
Dutch
10%
Bleeding
9%
Peripheral T-cell Lymphoma
9%
Hemostasis
8%
Acute Myeloid Leukemia
8%
Population-based
8%
Von Willebrand Factor
8%
Thrombosis
7%
Clinical Phenotype
7%
Odds Ratio
7%
Inherited Bleeding Disorders
7%
Leukemia Patients
7%
Survival Outcomes
7%
Clinical Outcomes
6%
Complete Remission
6%
Hazard Ratio
6%
Progression-free Survival
6%
Primary Central Nervous System Lymphoma (PCNSL)
6%
Polytherapy
6%
Clinical Survival
6%
Clinical Characteristics
6%
Consolidation Therapy
6%
Hypodysfibrinogenemia
6%
Valemetostat
6%
Total Thrombus-formation Analysis System
6%
Graft-versus-host Disease (GvHD)
6%
Enteropathy-associated T-cell Lymphoma
6%
Immunosuppression
6%
Prospective Randomized Trial
6%
Spatial Neighborhood
6%
Genetic Modification
6%
Remission Induction
6%
HER2+
6%
Physical Outcomes
6%
Body Composition
6%
Validation Studies
6%
Somatic Alterations
6%
Laboratory Detection
6%
Therapy Strategy
6%
Symptom Score
6%
Patient-reported Symptoms
6%
Knowledge Practices
6%
Phase II Study
6%
Knowledge Gaps
6%
Medical nutrition Therapy
6%
Chimerism
6%
Correlational Study
6%
Thrombus Formation
6%
Fecal Calprotectin
6%
Mucosal Inflammation
6%
Human Breast Cancer
6%
Natural Killer Cells
6%
Thrombotic
6%
Hematological Cancer
6%
On-state Current
6%
Home Testing
6%
Scoping Review
6%
Sexuality
6%
Human Epidermal Growth Factor Receptor 2 (HER2)
6%
Inflammatory Bowel Disease
6%
Atezolizumab
6%
Photoporation
6%
Nanosensitizers
6%
High Risk
6%
Pathophysiological Mechanisms
6%
R-CHOP
6%
Diffuse Large B-cell Lymphoma (DLBCL)
6%
National Survey
6%
Retrospective Analysis
6%
Secondary Central Nervous System Lymphoma
6%
Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL)
6%
Rotational Thromboelastometry (ROTEM)
6%
Large B-cell Lymphoma
6%
Hematotoxicity
6%
Chimeric Antigen Receptor T-cell Therapy
6%
Acute Myeloid Leukemia Cells
6%
CD70
6%
Antibody-dependent Cellular Cytotoxicity
6%
Cell Susceptibility
6%
Aplastic Anemia
6%
Clotting Factors
6%
Postpartum Hemorrhage
6%
Autologous Stem Cell Transplantation (auto-SCT)
6%
Routine Laboratory Data
6%
International Testing
6%
Leukemia Subtypes
6%
Clinically Significant
5%
Bleeding Tendency
5%
Remission
5%
Medicine and Dentistry
Bleeding Disorder
31%
Overall Survival
15%
Peripheral T-Cell Lymphoma
14%
Von Willebrand Disease
13%
Diseases
12%
Methotrexate
12%
Cohort Analysis
12%
Lochia
12%
Bleeding
11%
Autologous Stem Cell Transplantation
11%
Blood Stasis
9%
Third Trimester Pregnancy
9%
Von Willebrand Factor
8%
Neoplasm
8%
Anaplastic Large Cell Lymphoma
8%
Haemophilia A
8%
Thrombosis
7%
Hemostat
7%
Blood Clotting Factor
7%
Disease Free Survival
6%
Faecal Calprotectin
6%
Drug Megadose
6%
Primary Central Nervous System Lymphoma
6%
Combination Chemotherapy
6%
Valemetostat
6%
Enteropathy-Associated T-Cell Lymphoma
6%
Blood Clotting
6%
Natural Killer Cell
6%
Breast Cancer
6%
Spontaneous Remission
6%
Medical Nutrition Therapy
6%
Somatics
6%
Acute Myeloid Leukemia
6%
Inflammatory Bowel Disease
6%
Fibrinogen
6%
Arm
6%
Atezolizumab
6%
Diffuse Large B-Cell Lymphoma
6%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
6%
Central Nervous System
6%
Breast Implant
6%
Thymocyte Antibody
6%
Aplastic Anemia
6%
Bleeding Diathesis
5%
Laboratory Test
5%